| HOME >> BIOLOGY >> TECHNOLOGY |
Issuance of convertible royalty participation units - 7,737
Proceeds on exercise of stock options - 1
Proceeds on exercise of warrants 36 17
Repayment of capital lease obligation - (5)
-------------------------------------------------------------------------
Cash provided by financing activities $ 36 $ 7,750
-------------------------------------------------------------------------
Funds from (purchases of) short-term investments 6,880 (1,364)
Proceeds on disposal equipment 12 -
Purchases of equipment (75) (72)
-------------------------------------------------------------------------
Cash provided by (used in) investing activities $ 6,817 $ (1,436)
-------------------------------------------------------------------------
Increase in cash and cash equivalents $ 4,431 $ 3,206
Cash and cash equivalents, beginning of period 2,945 5,743
-------------------------------------------------------------------------
Cash and cash equivalents, end of period $ 7,376 $ 8,949
-------------------------------------------------------------------------
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the
area of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II
and preclinical), the prevention of catheter-related infections (Phase III)
and the treatment of dermatological diseases (Phase II). MIGENIX is
headquartered in Vancouver, British Columbia, Canada with US operations in
San Diego, C
'/>"/>
| SOURCE MIGENIX Inc. Copyright©2007 PR Newswire. All rights reserved |